COST-EFFECTIVENESS ANALYSIS OF TREATMENT TIMING CONSIDERING THE FUTURE ENTRY OF LOWER-COST GENERICS FOR HEPATITIS C

Cost-effectiveness analysis of treatment timing considering the future entry of lower-cost generics for hepatitis C

Katherine Heath1,2 1Mathematical Ecology Research Group, Department of Zoology, University of Oxford, Power Supplies Oxford OX1 3PS, UK; 2New College, Oxford OX1 3BN, UK Background: Cost-benefit analyses are crucial to inform treatment policies, particularly when the cost of patented drugs is very high.The cost of patented drugs is the limiting fac

read more